Hepatocellular carcinoma: perfusion quantification with dynamic contrast-enhanced MRI.

OBJECTIVE The objective of our study was to report our initial experience with dynamic contrast-enhanced MRI (DCE-MRI) for perfusion quantification of hepatocellular carcinoma (HCC) and surrounding liver. SUBJECTS AND METHODS DCE-MRI of the liver was prospectively performed on 31 patients with HCC (male-female ratio, 26:5; mean age, 61 years; age range, 41-83 years). A dynamic coronal 3D FLASH sequence was performed at 1.5 T before and after injection of gadolinium-based contrast agent with an average temporal resolution of 3.8 seconds. Regions of interest were drawn on the abdominal aorta, portal vein, liver parenchyma, and HCC lesions by two observers in consensus. Time-activity curves were analyzed using a dual-input single-compartment model. The following perfusion parameters were obtained: arterial flow, portal venous flow, arterial fraction, distribution volume, and mean transit time (MTT). RESULTS Thirty-three HCCs (mean size, 3.9 cm; range, 1.1-12.6 cm) were evaluated in 26 patients. When compared with liver parenchyma, HCC showed significantly higher arterial hepatic blood flow and arterial fraction (p < 0.0001) and significantly lower distribution volume and portal venous hepatic blood flow (p < 0.0001-0.023), with no difference in MTT. Untreated HCCs (n = 16) had a higher arterial fraction and lower portal venous hepatic blood flow value than chemoembolized HCCs (n = 17, p < 0.04). CONCLUSION DCE-MRI can be used to quantify perfusion metrics of HCC and liver parenchyma and to assess perfusion changes after HCC chemoembolization.

[1]  Edward Ashton,et al.  Dynamic Contrast-Enhanced Magnetic Resonance Imaging , 2012, Definitions.

[2]  Tao Jiang,et al.  Monitoring Response to Antiangiogenic Treatment and Predicting Outcomes in Advanced Hepatocellular Carcinoma Using Image Biomarkers, CT Perfusion, Tumor Density, and Tumor Size (RECIST) , 2012, Investigative radiology.

[3]  M. Mulcahy,et al.  Intraprocedural transcatheter intra-arterial perfusion MRI as a predictor of tumor response to chemoembolization for hepatocellular carcinoma. , 2011, Academic radiology.

[4]  J. Bruix,et al.  Management of hepatocellular carcinoma: An update , 2011, Hepatology.

[5]  Lawrence H. Schwartz,et al.  Antiangiogenic Therapy for Primary Liver Cancer: Correlation of Changes in Dynamic Contrast-Enhanced Magnetic Resonance Imaging with Tissue Hypoxia Markers and Clinical Response , 2011, Annals of Surgical Oncology.

[6]  G. Baron,et al.  Liver fibrosis in chronic hepatitis C virus infection: differentiating minimal from intermediate fibrosis with perfusion CT. , 2010, Radiology.

[7]  H. Rusinek,et al.  Diagnosis of cirrhosis with intravoxel incoherent motion diffusion MRI and dynamic contrast‐enhanced MRI alone and in combination: Preliminary experience , 2010, Journal of magnetic resonance imaging : JMRI.

[8]  T. Roskams,et al.  Pathology of early hepatocellular carcinoma: conventional and molecular diagnosis. , 2010, Seminars in liver disease.

[9]  L. Schwartz,et al.  Regional chemotherapy for unresectable primary liver cancer: results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  F. Fazio,et al.  Perfusion Computed Tomographic Assessment of Early Hepatocellular Carcinoma in Cirrhotic Liver Disease: Initial Observations , 2008, Journal of computer assisted tomography.

[11]  C. Thng,et al.  Hepatic metastases: in vivo assessment of perfusion parameters at dynamic contrast-enhanced MR imaging with dual-input two-compartment tracer kinetics model. , 2008, Radiology.

[12]  J. Mabrut,et al.  Characterization of hepatocellular carcinoma and colorectal liver metastasis by means of perfusion MRI , 2008, Journal of magnetic resonance imaging : JMRI.

[13]  Dieter Häussinger,et al.  Sorafenib in advanced hepatocellular carcinoma. , 2008, The New England journal of medicine.

[14]  D. Collins,et al.  Quantitative mapping of hepatic perfusion index using MR imaging: a potential reproducible tool for assessing tumour response to treatment with the antiangiogenic compound BIBF 1120, a potent triple angiokinase inhibitor , 2008, European Radiology.

[15]  H. Rusinek,et al.  Advanced liver fibrosis: diagnosis with 3D whole-liver perfusion MR imaging--initial experience. , 2008, Radiology.

[16]  Henry Rusinek,et al.  Quantitative determination of Gd‐DTPA concentration in T1‐weighted MR renography studies , 2007, Magnetic resonance in medicine.

[17]  N. Holalkere,et al.  Advanced hepatocellular carcinoma: CT perfusion of liver and tumor tissue--initial experience. , 2007, Radiology.

[18]  D. Amadori,et al.  Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  A. Kirsch,et al.  Dynamic contrast-enhanced MR urography in the evaluation of pediatric hydronephrosis: Part 1, functional assessment. , 2005, AJR. American journal of roentgenology.

[20]  R. O'Gorman,et al.  Comparison of the hepatic perfusion index measured with gadolinium-enhanced volumetric MRI in controls and in patients with colorectal cancer. , 2005, The British journal of radiology.

[21]  J. Bruix,et al.  Chemoembolization for hepatocellular carcinoma. , 2004, Gastroenterology.

[22]  Jane Wang,et al.  Dynamic contrast-enhanced MRI analysis of perfusion changes in advanced hepatocellular carcinoma treated with an antiangiogenic agent: a preliminary study. , 2004, AJR. American journal of roentgenology.

[23]  B. V. Van Beers,et al.  Hepatic flow parameters measured with MR imaging and Doppler US: correlations with degree of cirrhosis and portal hypertension. , 2003, Radiology.

[24]  C. Sempoux,et al.  Capillarization of the sinusoids in liver fibrosis: Noninvasive assessment with contrast‐enhanced MRI in the rabbit , 2003, Magnetic resonance in medicine.

[25]  A. Padhani Dynamic contrast‐enhanced MRI in clinical oncology: Current status and future directions , 2002, Journal of magnetic resonance imaging : JMRI.

[26]  B. V. Van Beers,et al.  Assessment of hepatic perfusion parameters with dynamic MRI , 2002, Magnetic resonance in medicine.

[27]  S. Fan,et al.  Microvessel density, vascular endothelial growth factor and its receptors Flt-1 and Flk-1/KDR in hepatocellular carcinoma. , 2001, American journal of clinical pathology.

[28]  R Materne,et al.  Hepatic perfusion parameters in chronic liver disease: dynamic CT measurements correlated with disease severity. , 2001, AJR. American journal of roentgenology.

[29]  A. Padhani Dynamic contrast-enhanced MRI studies in human tumours. , 1999, The British journal of radiology.

[30]  K. Plate,et al.  Vascular endothelial growth factor , 1997, Journal of Neuro-Oncology.

[31]  A R Padhani,et al.  Probing tumor microvascularity by measurement, analysis and display of contrast agent uptake kinetics , 1997, Journal of magnetic resonance imaging : JMRI.

[32]  E. Rostrup,et al.  Myocardial perfusion modeling using MRI , 1996, Magnetic resonance in medicine.

[33]  H. Dvorak,et al.  Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. , 1995, The American journal of pathology.

[34]  D. Connolly Vascular permeability factor: A unique regulator of blood vessel function , 1991, Journal of cellular biochemistry.

[35]  M. Kojiro,et al.  Pathologic Characteristics of Hepatocellular Carcinoma , 1986, Seminars in liver disease.

[36]  J. Kao,et al.  Dynamic contrast-enhanced magnetic resonance imaging with Gd-EOB-DTPA for the evaluation of liver fibrosis in chronic hepatitis patients , 2011, European Radiology.

[37]  F. Fazio,et al.  Perfusion CT in cirrhotic patients with early stage hepatocellular carcinoma: assessment of tumor-related vascularization. , 2010, European journal of radiology.

[38]  H. Naora,et al.  Requisite role of VEGF receptors in angiogenesis of hepatocellular carcinoma: a comparison with angiopoietin/Tie pathway. , 2002, Anticancer research.